LQDA vs UTHR
LQDA: A biopharmaceutical company revolutionizing treatment for pulmonary hypertension using its proprietary PRINT particle engineering technology and treprostinil-based therapies. UTHR: United Therapeutics is a biotechnology company dedicated to providing innovative, life-extending therapies for patients with pulmonary arterial hypertension and other rare diseases through a focus on proprietary treprostinil-based treatments.
Side-by-side fundamentals
| Metric | LQDA | UTHR | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $28.02 | $532.78 | |
| Market cap as of 2026-07-29 (share count; price 2026-10-08) | $2.5B | $22.9B | |
| P/E as of 2026-10-08 | 171.80 | 19.06 | UTHR lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 0.83 | |
| Net margin FY2025, SEC XBRL | -43.5% | +41.9% | UTHR higher |
| Gross margin FY2025, SEC XBRL | n/a | +87.9% | |
| Operating margin FY2025, SEC XBRL | -32.5% | +46.9% | UTHR higher |
| ROE FY2025, SEC XBRL | -154.0% | +18.8% | UTHR higher |
| ROA FY2025, SEC XBRL | -21.0% | +16.9% | UTHR higher |
| Debt / equity as of 2026-09-03 | 1.64 | 0.00 | UTHR lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +2.5% | |
| Revenue CAGR (3y) SEC XBRL | +115.0% | +18.0% | LQDA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.00 | 0.39 | |
| 1-year return as of 2026-10-08 close | +16.4% | +18.7% | UTHR higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.